Today: August 24, 2017, 8:57 am
  
Health

Now Available: Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017

New Drug Pipeline research report from Global Markets Direct is now available from Fast Market Research
Now Available: Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017
PR-Inside.com: 2017-05-19 17:02:56
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides an overview of the Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.


Full Report Details at
- www.fastmr.com/prod/1279344_crohn_disease_regional.aspx?afid=701

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 11, 28, 25, 37, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

* The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis) (Gastrointestinal).
* The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
* The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
* The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
* The pipeline guide reviews key companies involved in Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
* The pipeline guide evaluates Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
* The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
* The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal)

Reasons to Get this Report

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal).
* Classify potential new clients or partners in the target demographic.
* Develop tactical initiatives by understanding the focus areas of leading companies.

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033&afid=701

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information


Published by
Bill Thompson
18008448156
e-mail
www.fastmr.com



# 784 Words
Related Articles
More From The Author
Fluxion Biosciences Inc - Product Pipeline Analysis, [..]
Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical and live cell analysis tools. The company's products include [..]
Market Report, "TrendSights Analysis: Personalization", published
TrendSights Analysis: Personalization, is part of GlobalData's TrendSights series and explores how brands can provide a superior [..]
Just Published: "Overactive Bladder - Pipeline Review, [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 [..]
New Market Research Report: Wealth in the [..]
Wealth in the UK: HNW Investors 2017, analyzes the investing preferences and portfolio allocation of UK HNW investors. The report [..]
The Cards and Payments Industry in Taiwan [..]
GlobalData's "The Cards and Payments Industry in Taiwan - Emerging Trends and Opportunities to 2021", report provides detailed [..]
 
More From Health
Invacare International take powerchairs to a new [..]
Touch screen remote Introducing next generation technology to powerchairs, Invacare is pleased to present the REM400 remote with [..]
Award Winning Ambient Noise App TaoMix 2 [..]
MONTREAL, CANADA – August 16, 2017 – Available today on Google Play, TaoMix 2 makes it easy for anyone to [..]
Riverside Clinic FB Source of Inspiring Articles [..]
Riverside Clinic is an addiction treatment service for individuals suffering due to substance abuse disorders. The Melbourne-based centre [..]
Singapore eDevelopment Biomedical Subsidiary Partners Chemia [..]
SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore Exchange Catalist-listed Singapore eDevelopment Limited ("SeD") announced [..]
Experience the Benefits of Croton Essential Oils [..]
New Delhi, Friday, August 11, 2017: Essential Oils are one of the most popular natural products that people all over [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.